FDA panel splits on Pulminiq

Chiron's Pulminiq -- a treatment for preventing lung transplant rejection -- has received a split decision by an influential FDA advisory panel. The panel voted 8-8 on Pulminiq after staffers had questioned the accuracy of data drawn from a small clinical trial. The trial found a 79 percent reduction in the risk of death among the 26 patients using the drug. Some members of the panel wondered if other factors could have influenced the data. The drug is only a small one for Chiron, though, with an estimated market value of $40 million to $75 million. The FDA will now take up the issue and decide by July 14.

- read this article from the San Francisco Chronicle

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.